Send to

Choose Destination
Hum Gene Ther. 2009 Aug;20(8):796-806. doi: 10.1089/hum.2009.094.

Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies.

Author information

Department of Pediatrics, Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610, USA.


The ability of recombinant adeno-associated viral (rAAV) vectors to exhibit minimal immunogenicity and little to no toxicity or inflammation while eliciting robust, multiyear gene expression in vivo are only a few of the salient features that make them ideally suited for many gene therapy applications. A major hurdle for the use of rAAV in sizeable research and clinical applications is the lack of efficient and versatile large-scale production systems. Continued progression toward flexible, scalable production techniques is a prerequisite to support human clinical evaluation of these novel biotherapeutics. This review examines the current state of large-scale production methods that employ the herpes simplex virus type 1 (HSV) platform to produce rAAV vectors for gene delivery. Improvements have substantially advanced the HSV/AAV hybrid method for large-scale rAAV manufacture, facilitating the generation of highly potent, clinical-grade purity rAAV vector stocks. At least one human clinical trial employing rAAV generated via rHSV helper-assisted replication is poised to commence, highlighting the advances and relevance of this production method.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Mary Ann Liebert, Inc. Icon for PubMed Central
Loading ...
Support Center